Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: The current knowledge about the role of comorbidities in systemic sclerosis (SSc) is limited. Therefore, the aim of this study was to evaluate the prevalence of comorbidities and their impact on disease activity and prognosis in the Systemic sclerosis PRogression INvestiGation (SPRING) registry.
Methods: SSc patients from the SPRING registry, fulfilling the ACR/EULAR 2013 classification criteria, with complete data on baseline comorbidities were enrolled. The Charlson comorbidity index (CCI) was used to quantify the overall comorbidity burden. The disease activity was calculated using the revised EUSTAR activity index (AI). The impact of SSc features on CCI, the effect of CCI on SSc disease activity and mortality were tested with multivariable regression models.
Results: Among 1910 SSc patients enrolled, 67.3 % had at least one comorbidity at baseline. The most frequent comorbidities were systemic arterial hypertension (23.7 %), osteoporosis (12.9 %) and dyslipidemia (11 %). The mean value of CCI score was 2.0 ± 1.8. When patients were grouped according to increasing levels of CCI, a clear separation in the distribution of SSc-related clinical features could be observed. Among over 900 patients with available follow-up, no association between baseline CCI and changes in disease activity was observed. Conversely, the risk of death over time was independently predicted by both CCI and AI.
Conclusions: Comorbidities and disease activity independently impact on the prognosis of SSc patients. This suggests that the management of comorbidities, together with the reduction of disease activity, is fundamental to improve patient survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejim.2024.07.040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Digital Cueing With Laser Shoes Does Not Improve Walking in Parkinson's Disease: Evidence Across Disease Severity and Freezing Status.
Neurorehabil Neural Repair
September 2025
Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon Tyne, UK.
Background: Gait impairment in Parkinson's disease (PD) occurs early and pharmaceutical interventions do not fully restore this function. Visual cueing has been shown to improve gait and alleviate freezing of gait (FOG) in PD. Technological development of digital laser shoe visual cues now allows for visual cues to be used continuously when walking.
View Article and Find Full Text PDFWhere we Live matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States.
Arthritis Rheumatol
September 2025
Washington DC Veterans Affairs Medical Center; Georgetown University, Washington, DC, USA.
Objective: To evaluate the clinical characteristics, social deprivation, insurance coverage, and medication use across regional subsets of patients with psoriatic arthritis (PsA) in the US.
Methods: A cross-sectional study of PsA patients in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March2023 was conducted. Distribution of high disease activity (HDA - RAPID3>12), high comorbidity (RxRisk ≥90 percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10mg daily, and all DMARD therapies across geographic regions were evaluated.
IGLV3-21-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.
Haematologica
September 2025
Division of Medical Oncology, University Hospital Basel, Basel, Switzerland; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel.
We previously used a disease-specific B cell receptor (BCR) point mutation (IGLV3-21R110) for selective targeting of a high-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR) T cells. Since CLL is a disease of the elderly and a significant fraction of patients is not able to physically tolerate CAR T cell treatment, we explored bispecific antibodies as an alternative for precision targeting of this tumor mutation. Heterodimeric IgG1-based antibodies consisting of a fragment crystallizable region (Fc) attached to both an anti-IGLV3-21R110 Fab and an anti-CD3 (UCHT1) single chain variable fragment (R110-bsAb) selectively killed cell lines engineered to express high levels of the neoepitope as well as primary CLL cells using healthy donor and CLL patient-derived T cells as effectors.
View Article and Find Full Text PDFEarly cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells.
Haematologica
September 2025
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD,.
Immunotherapies, including cell therapies, are effective anti-cancer agents. However, cellular product persistence can be limiting with short functional duration of activity contributing to disease relapse. A variety of manufacturing protocols are used to generate therapeutic engineered T-cells; these differ in techniques used for T-cell isolation, activation, genetic modification, and other methodology.
View Article and Find Full Text PDFEffect of Western diet on body composition, locomotor performance and blood biochemical profile in the bank vole.
J Exp Biol
September 2025
Institute of Environmental Sciences, Faculty of Biology, Jagiellonian University, Kraków, Poland.
The adverse effects of Western diets (WD), high in both fat and simple sugars, which contribute to obesity and related disorders, have been extensively studied in laboratory rodents, but not in non-laboratory animals, which limits the scope of conclusions. Unlike laboratory mice or rats, non-laboratory rodents that reduce body mass for winter do not become obese when fed a high-fat diet. However, it is not known whether these rodents are also resistant to the adverse effects of WD.
View Article and Find Full Text PDF